Hepatocellular carcinoma is the most common primary liver malignancy, accounting for 85 to 90 percent of cancers that originate in liver cells, and it ranks as the third leading cause of cancer-related death worldwide. For patients with intermediate-stage disease and preserved liver function, transarterial chemoembolization, or TACE, is a cornerstone of care under the Barcelona Clinic Liver Cancer staging system. The procedure exploits a biological quirk: liver tumors draw their blood supply almost exclusively from the hepatic arteries, while healthy liver tissue depends on the portal vein. By threading a catheter into the arteries feeding the tumor and delivering a mixture of chemotherapy and an oily contrast agent called lipiodol, followed by embolization with gel foam slurry, interventional radiologists can concentrate a cytotoxic assault on the tumor while starving it of blood.

Yet the very act of delivering that assault exposes the hepatic vasculature to a barrage of insults. Catheters and guidewires scrape the vessel walls. Lipiodol and antimitotic drugs such as epirubicin exert corrosive and chemical effects on the delicate endothelial lining. Temporary embolization produces ischemic stress, and patients with chronic liver disease already harbor dysfunctional endothelium that may be poorly equipped to recover. Despite decades of TACE practice, the literature on what actually happens to the native hepatic arteries after treatment has remained surprisingly thin, prompting the research team to investigate systematically.

The researchers, led by interventional radiologists at the Sree Chitra Tirunal Institute for Medical Sciences and Technology in Thiruvananthapuram, Kerala, combed hospital records for all adult patients with chronic liver disease who underwent more than one session of TACE between January 2018 and June 2023. Of 394 patients treated during that window, 69 had undergone repeat sessions, and 58 had angiographic images of sufficient quality for analysis. The team deliberately excluded patients who had received other locoregional therapies, such as radiofrequency ablation, between TACE sessions, to keep the vascular picture as clean as possible.

The analytical framework was elegantly simple. The hepatic vasculature was divided into three anatomical zones: the proximal zone comprising the common hepatic artery and hepatic artery proper, the intermediate zone covering lobar and segmental branches, and the distal zone encompassing the subsegmental branches that represent the liver’s microvascular frontier. Injury was graded on a four-point ordinal scale, ranging from Grade 0 for a normal appearance or mild irregularity, through Grade 1 for mild stenosis of about 50 percent, to Grade 2 for severe stenosis or complete occlusion, and Grade 3 for the presence of pseudoaneurysms or dysplastic arterial changes. Grades 0 and 1 were classified as low-grade injury, while Grades 2 and 3 counted as high-grade. Two radiologists with ten and five years of gastrointestinal imaging experience independently reviewed paired angiograms obtained at least six weeks apart, blinded to clinical details.

The results painted a strikingly zonal picture. In the proximal vessels, 98.3 percent of patients showed Grade 0 injury and the remainder Grade 1, with no high-grade damage at all, and statistical testing confirmed no significant change before and after the first TACE session. The intermediate zone told a different story: 84.5 percent of patients had Grade 0 injury, but 13.8 percent showed Grade 1 and 1.7 percent showed Grade 2, a distribution that shifted significantly after treatment. The distal subsegmental vasculature fared worst of all, with 53.4 percent of patients at Grade 0, 31 percent at Grade 1, 13.8 percent at Grade 2, and 1.7 percent at Grade 3, meaning roughly 12 to 15.5 percent of patients developed high-grade injury to the liver’s smallest arteries. The Mann-Whitney U-test yielded p-values of 0.002 for the intermediate zone and 0.001 for the distal zone, while the proximal zone showed no significant difference. Interobserver agreement was strong, with a correlation coefficient of 0.913.

To understand why some patients’ microvasculature fared worse than others, the team turned to multinomial logistic regression, feeding in demographic, biochemical, clinical and procedural variables. Three factors emerged as independent predictors of high-grade distal arterial injury: the Child-Pugh score, a measure of liver functional reserve; the presence of diabetes; and the delta time, the interval in weeks between successive TACE sessions. Each carried a statistically significant association, with p-values of 0.031, 0.045 and 0.004 respectively. Notably, no variable predicted high-grade injury in the lobar and segmental vessels, reinforcing the impression that the microvasculature is uniquely vulnerable.

The biology behind these predictors is plausible. Diabetes is well known to impair endothelial function and blunt vascular healing, and prior work has shown that adequate glycemic control in TACE patients is associated with improved progression-free survival. Deteriorating liver function, captured by the Child-Pugh score, is likewise linked to poor endothelial resilience and impaired microvascular recovery. The delta time finding may be the most immediately actionable: shorter intervals between embolization sessions give the injured native vasculature less time to recover, so repetitive injury at close intervals compounds itself. This inverse relationship between retreatment interval and vascular damage could inform scheduling decisions, suggesting that clinicians may want to prioritize vascular recovery when planning repeat interventions rather than compressing the timeline.

The clinical stakes are considerable. Patency of segmental and subsegmental arteries is paramount for delivering a second round of chemoembolization to residual or recurrent tumor, so distal vascular injury could compromise both the feasibility and efficacy of retreatment, and may even encourage the tumor to recruit alternative extrahepatic blood supplies. Conversely, the apparent invulnerability of the proximal hepatic arteries is reassuring for the substantial subset of patients who undergo TACE as a bridge to liver transplantation, since damage to the main hepatic artery could complicate the transplant operation itself. Prior multicenter analyses of more than 800 patients who received TACE before transplantation found no increased need for intraoperative hepatic artery interventions, a conclusion this study’s proximal findings echo. The authors also raise the possibility that transarterial radioembolization, generally considered gentler on the vasculature, may be preferable for patients anticipated to need multiple locoregional treatments.

The study has limitations that temper but do not erase its message. It assessed only the changes following the first TACE session to maintain homogeneity, so cumulative injury from multiple sessions remains unmeasured. It was a single-center analysis with a modest sample, and all patients received conventional TACE rather than drug-eluting bead or balloon-occlusion variants, so the findings may not generalize to those techniques. Still, the authors report that no previous study has systematically documented the incidence of hepatic arterial injury after chemoembolization, making this a genuine first. Larger, prospective, multicenter trials will be needed to confirm the predictors and to determine whether protecting the liver’s smallest arteries can translate into better outcomes for patients facing repeated rounds of therapy against one of the world’s deadliest cancers.

Subject of Research: Vascular injury to hepatic arteries following transarterial chemoembolization for hepatocellular carcinoma

Article Title: Angio-architectural changes in hepatic arteries following conventional transarterial chemoembolization for hepatocellular carcinoma and the factors influencing them: a retrospective observational study

Article References: Arunachalam, V. S., Sharma, S., Ayyappan, A., Alex, A., & Valakkada, J. (2025). Angio-architectural changes in hepatic arteries following conventional transarterial chemoembolization for hepatocellular carcinoma and the factors influencing them: a retrospective observational study. CVIR Oncology, 1(1), Article 28. https://doi.org/10.1007/s44343-025-00028-w

Image Credits: AI Generated

DOI: 10.1007/s44343-025-00028-w

Keywords: hepatocellular carcinoma, transarterial chemoembolization, hepatic artery, vascular injury, interventional radiology, angiography, microvasculature, Child-Pugh score, diabetes, lipiodol, liver cancer, endothelial dysfunction

TARE has become a mainstay of modern liver cancer care because of its unusual elegance. Rather than flooding the whole body with chemotherapy, clinicians deliver yttrium-90, a beta-emitting isotope bound to glass or resin microspheres roughly the width of a red blood cell, directly into the arteries that feed the tumor. The spheres lodge in the small vessels surrounding the malignancy and bathe it in high-dose radiation while sparing most healthy tissue. The technique works across the full spectrum of liver cancer severity, from early-stage disease where it can bridge patients to transplant, to advanced stages where it serves primarily to control tumor growth. Its safety record is genuinely impressive: serious adverse events occur in only about nine percent of patients, and vascular injury is estimated at no more than one percent of cases, typically arising when arterial anatomy is unusually complex, vessels have been weakened by prior chemotherapy, or pre-existing vascular abnormalities are present.

The Swiss case began conventionally enough. The patient, a man in his early seventies with liver fibrosis caused by chronic hepatitis C, was found on ultrasound to have a thirty-millimeter lesion in segment VIII of the liver, near the organ’s central hilum where major bile ducts and blood vessels converge. Magnetic resonance imaging and biopsy confirmed a moderately differentiated hepatocellular carcinoma, staged at an early BCLC stage with well-preserved liver function. A multidisciplinary tumor board weighed the options carefully. Percutaneous ablation, usually the first choice for small tumors, was judged too risky because of the lesion’s close proximity to a portal vein branch and the biliary tree. The team instead selected TARE, planning a curative dose of yttrium-90 glass microspheres engineered to deliver an estimated 324 gray to the perfused liver and more than a thousand gray to the tumor itself.

The workup phase went smoothly. Angiography revealed an anatomical quirk, a common hepatic artery arising from the superior mesenteric artery rather than its usual origin, but the team successfully navigated the tortuous route, advanced a microcatheter into the anterior sectoral artery supplying the tumor, and confirmed excellent targeting with technetium-99m-labeled macroaggregated albumin, the standard pre-treatment tracer. Two weeks later, during the therapeutic session, the trouble started. As the microcatheter was advanced along the same vessel, it caused a focal iatrogenic dissection, a tear in the arterial lining that separated the vessel wall into a true lumen and a false channel. Dissections of this kind are a recognized hazard of catheter work; guidelines from the Society of Interventional Radiology suggest they should prevent completion of the intended treatment in fewer than one percent of cases.

The team responded with textbook technique. They swapped the stiffer 2.7 French microcatheter for a softer, more flexible 1.98 French device paired with a fine guidewire, and successfully re-entered the true lumen. Digital subtraction angiography visualized the dissection, but selective intra-arterial CT angiography, a more detailed cross-sectional view taken from inside the vessel, showed no contrast stagnation in the false lumen, no pooling around the catheter tip, and preserved tumor enhancement that looked essentially identical to the simulation phase. Encouraged by these images, the physicians proceeded and administered 2.9 gigabecquerels of yttrium-90. Only afterward did post-treatment positron emission tomography reveal the flaw in that confidence: focal radioactive tracer uptake outside the liver tissue, in the region of the hepatic hilum, exactly where the dissection had occurred. Dosimetry calculations estimated that some 678 gray of radiation, an extraordinary dose by any standard, had pooled on the damaged arterial wall.

The critical insight, one the authors emphasize with some force, is that contrast dye is not a reliable proxy for microsphere behavior. Contrast agents and yttrium-90 spheres differ in particle size, density, and the way they move with blood flow, so a vessel that appears well perfused on angiography can still trap radioactive particles unevenly. In this patient, the dissection created abnormal flow conditions at the hepatic hilum that the intraprocedural imaging could not fully resolve. The spheres that should have been distributed throughout the tumor instead accumulated along an injured arterial wall, setting the stage for a form of collateral damage that is rarely reported and poorly understood: radiation-induced arteritis of the liver’s major vessels.

Because the patient remained symptom-free, he was discharged with daily telephone monitoring and a scheduled CT angiography seven days later, a deliberate precaution given the enormous extraparenchymal dose. That scan proved decisive. It revealed diffuse arteriopathy involving the common, right, and left hepatic arteries and their proximal branches, with multiple wall irregularities and three pseudoaneurysms, the largest measuring seven millimeters in the right hepatic artery. Pseudoaneurysms are balloon-like outpouchings formed when a weakened vessel wall balloons outward under pressure, and their rupture can trigger catastrophic intra-abdominal hemorrhage. The rapid onset of these changes, detectable within a single week, suggested a sinister synergy: mechanical injury from the catheter tearing the intima, compounded almost immediately by yttrium-90 radiation destroying the endothelial cells and muscular media of the vessel wall beneath.

The pathophysiology of radiation-induced vascular injury has been studied mostly in the context of external beam radiotherapy, where it is known to involve endothelial cell death, necrosis of the arterial media, and scarring of the adventitia that progressively narrows vessels or erodes them into aneurysms. Whether the same mechanisms unfold in the intrahepatic circulation after internal radiation has been largely uncharted territory. To the authors’ knowledge, no previous case has documented an iatrogenic arterial dissection during TARE evolving into subacute radiation-associated arteriopathy, which is precisely what makes the report valuable and unsettling. After urgent multidisciplinary consultation and shared decision-making with the patient, the team performed prophylactic coil embolization, deploying a series of detachable and pushable platinum coils through the hepatic arteries to pack shut the abnormal segments. Because the pathology was diffuse and multifocal, a covered stent, which would have preserved the vessel while sealing it, was not feasible, so the physicians accepted permanent sacrifice of the arterial tree. The patient’s preserved Child-Pugh A liver function and compensatory portal venous blood supply made the risk acceptable, though the team openly acknowledged a sobering trade-off: closing these arteries eliminated any possibility of future endovascular treatments if the cancer returned.

The outcome was, by any measure, a success story wrapped around a cautionary tale. Final angiography confirmed complete exclusion of the pseudoaneurysms and abnormal vessels, and transiently elevated liver enzymes normalized within five days. Magnetic resonance imaging at four weeks and three months showed a complete response of the original tumor by RECIST 1.1 criteria, with no biliary injury or hepatic ischemia, and preserved liver function throughout follow-up. A small new lesion in a distant segment was later treated successfully with percutaneous radiofrequency ablation. The authors distill the experience into several key lessons: anticipate vascular injury in patients with complex anatomy, reconsider microsphere delivery whenever arterial dissection occurs, maintain close post-procedural surveillance to catch vascular complications early, and weigh carefully whether definitive arterial embolization forecloses future treatment options. In asymptomatic patients, surveillance alone may suffice, since small pseudoaneurysms can stabilize or resolve, but their natural history is unpredictable and rupture can be lethal, so management must be individualized. For a procedure performed tens of thousands of times each year, this single case is a powerful reminder that even a one-percent risk deserves a protocol, and that the liver’s arteries, once injured and then irradiated, can fail in ways we are only beginning to describe.

Subject of Research: Iatrogenic arterial dissection during transarterial radioembolization leading to radiation-induced hepatic arteritis

Article Title: Iatrogenic arterial dissection leading to radiation induced arteritis following transarterial radioembolization

Article References: Adami, M., Boughdad, S., Villard, N., Schaefer, N., Rafael, D., & Tsoumakidou, G. (2026). Iatrogenic arterial dissection leading to radiation induced arteritis following transarterial radioembolization. CVIR Oncology, 2(1), Article 25. https://doi.org/10.1007/s44343-026-00061-3

Image Credits: AI Generated

DOI: 10.1007/s44343-026-00061-3

Keywords: transarterial radioembolization, hepatocellular carcinoma, yttrium-90, arterial dissection, radiation-induced arteritis, hepatic artery, pseudoaneurysm, coil embolization, interventional radiology, dosimetry, vascular complication, case report